How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

| More on:
a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Ltd (ASX: COH) shares have been bouncing around on Thursday.

In morning trade, the hearing solutions company's shares were down as much as 4.5% to $256.43.

But this afternoon, they have started to recover and currently sit 0.5% lower for the day at $266.74.

What is going on with Cochlear shares?

The company's shares were caught up in a broad market selloff this morning after US President Donald Trump made his big announcement.

From Saturday, the United States will put a minimum 10% tariff on foreign imports, including those from Australia, as part of what Trump has dubbed his "liberation day" economic plan.

This has been bad news for a number of ASX shares, such as Ansell Ltd (ASX: ANN), Breville Group Ltd (ASX: BRG), Lovisa Holdings Ltd (ASX: LOV), and Cettire Ltd (ASX: CTT). They have all fallen heavily today amid concerns over the impact that the trade tariffs could have on their respective businesses.

But what about Cochlear? How will it be impacted?

Well, the short answer is we don't know yet. Until greater detail is provided, Cochlear advised that it is unsure what the impact will be. However, there is reason to hope that the impact will not be material. This may explain why Cochlear shares have recovered from their intraday lows this afternoon.

Cochlear response

This morning, Cochlear released an announcement, explaining that it was a complex situation. It said:

There are complexities in understanding the application of the new tariff. Cochlear has long been importing its products under a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products into the US, including hearing implants. We are expecting further detail in the US Customs and Border Protection Notice of Implementation, which is expected to be published in the next week. An update will be provided to the market in due course.

Judging by the way that Cochlear's shares have recovered today, it seems that some investors believe that the company will escape from the wrath of Trump's tariffs. Though, that will not be known for sure until the company releases a follow up announcement next week or the week after.

For now, the team at Citi are likely to see recent weakness as a buying opportunity. A note from last month reveals that the broker has a buy rating and $300.00 price target on the company's shares.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 3 April 2025

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Cochlear and Lovisa. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Lovisa. The Motley Fool Australia has recommended Ansell, Cochlear, and Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Why FDA approval could turn this ASX All Ords company into a multibagger

Despite surging more than 230% in the past year, this company might be on its way to becoming a much…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

Canaccord Genuity recommends a 'basket approach' when investing in these types of stocks.

Read more »

A worried woman looks at her phone and laptop, seeking ways to tighten her belt against inflation.
Healthcare Shares

This ASX share potentially 'has no value from here', says broker

This is every investor's worst nightmare.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Should I buy Fisher & Paykel or ResMed shares?

Let's see which of these two names could be best buys.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This company has entered a trading halt, is it about to announce FDA approval?

This regenerative medicine company is up more than 260% in the last year.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

3 reasons to buy this surging ASX All Ords healthcare share today

A top expert forecasts more outperformance from this rocketing ASX healthcare stock.

Read more »